The clinical relevance of circulating, exosomal miRNAs as biomarkers for cancer
Standard
The clinical relevance of circulating, exosomal miRNAs as biomarkers for cancer. / Schwarzenbach, Heidi.
In: EXPERT REV MOL DIAGN, Vol. 15, No. 9, 2015, p. 1159-69.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - The clinical relevance of circulating, exosomal miRNAs as biomarkers for cancer
AU - Schwarzenbach, Heidi
PY - 2015
Y1 - 2015
N2 - In cancer, deregulated expression levels of miRNAs are associated with tumorigenesis, tumor progression, metastasis and drug resistance. Apart from their release by apoptotic and necrotic cells, miRNAs can also be actively secreted into the blood circulation by exosomes. Exosomal miRNAs are thought to play an important role in cell-to-cell communication. Based on their biological functions and the possibility of quantifying miRNAs in patient blood in real time, these small non-coding RNA molecules may be a new promising class of potential non-invasive biomarkers. Screening of these liquid biopsies may provide information on target molecules of miRNAs and aberrant signaling pathways that can be blocked by a chosen targeted therapy. Consequently, therapy-associated modulations may facilitate treatment decisions. The present article discusses the potential clinical use of exosomal miRNAs as diagnostic and prognostic tumor markers. The emerging role of exosomes as a mediator of cell-to-cell signaling, to transfer miRNAs between cells, is also discussed.
AB - In cancer, deregulated expression levels of miRNAs are associated with tumorigenesis, tumor progression, metastasis and drug resistance. Apart from their release by apoptotic and necrotic cells, miRNAs can also be actively secreted into the blood circulation by exosomes. Exosomal miRNAs are thought to play an important role in cell-to-cell communication. Based on their biological functions and the possibility of quantifying miRNAs in patient blood in real time, these small non-coding RNA molecules may be a new promising class of potential non-invasive biomarkers. Screening of these liquid biopsies may provide information on target molecules of miRNAs and aberrant signaling pathways that can be blocked by a chosen targeted therapy. Consequently, therapy-associated modulations may facilitate treatment decisions. The present article discusses the potential clinical use of exosomal miRNAs as diagnostic and prognostic tumor markers. The emerging role of exosomes as a mediator of cell-to-cell signaling, to transfer miRNAs between cells, is also discussed.
U2 - 10.1586/14737159.2015.1069183
DO - 10.1586/14737159.2015.1069183
M3 - SCORING: Journal article
C2 - 26202667
VL - 15
SP - 1159
EP - 1169
JO - EXPERT REV MOL DIAGN
JF - EXPERT REV MOL DIAGN
SN - 1473-7159
IS - 9
ER -